Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
Testing the Efficacy of Multi-day Interruptions in Sedentary Behaviors on Metabolic, Cognitive, and Affective Outcomes in Youth at Risk for Type 2 Diabetes
1 other identifier
interventional
188
1 country
1
Brief Summary
The overall objective of this in-lab randomized controlled trial is to test the efficacy of multi-day interruptions in sedentary behavior vs. single bouts of sustained exercise on metabolic, cognitive, affective, and cardiac autonomic nervous system responses in children with overweight and obesity who are at risk for type 2 diabetes. The use of continuous glucose monitoring will provide insight into the daily and cumulative metabolic effects of each condition that have thus far not been studied. In-lab studies demonstrating sustained efficacy of this approach in ameliorating negative effects of sedentary behaviors in children are necessary for the optimization of field-based interventions. Given the lack of success of interventions to prevent obesity-related diseases and increasing rates of type 2 diabetes in children and its related healthcare costs, this study addresses a critical public health need by testing of novel intervention strategies to reduce obesity-related diseases in children with overweight and obesity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2020
CompletedFirst Posted
Study publicly available on registry
July 14, 2020
CompletedStudy Start
First participant enrolled
March 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
June 5, 2025
June 1, 2025
4.4 years
May 20, 2020
June 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
In-Lab glucose area under the curve (AUC)
change in glucose AUC from oral glucose tolerance tests
3 hours (-10, 0, 30, 60, 90, 120, 150, 180 minutes) AUC change from Day 1 to Day 7
In-Lab insulin area under the curve (AUC)
change in insulin AUC from oral glucose tolerance tests
3 hours (-10, 0, 30, 60, 90, 120, 150, 180 minutes) AUC change from Day 1 to Day 7
In-Lab c-peptide area under the curve (AUC)
change in c-peptide AUC from oral glucose tolerance tests
3 hours (-10, 0, 30, 60, 90, 120, 150, 180 minutes) AUC change from Day 1 to Day 7
Continuous glucose monitor measures
mean daily 24-hr glucose area under the curve (AUC)
7 days
Secondary Outcomes (4)
Cognitive function measures
change from Day 1 to Day 7
Positive and Negative Affect Scale for Children
change from Day 1 to Day 7
State-Trait Anxiety Inventory for Children (STAIC)
change from Day 1 to Day 7
Cardiac autonomic nervous system measures
7 days
Study Arms (3)
SIT
NO INTERVENTIONContinuous sitting for 3 hours
SIT+WALK
EXPERIMENTALInterrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
EX
EXPERIMENTALPerform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
Interventions
Eligibility Criteria
You may qualify if:
- Age 8-11 years-old
- Good general health
- BMI≥85th percentile
You may not qualify if:
- Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion
- Diagnosis of T2DM and/or presence of other endocrinologic disorders leading to obesity (e.g., Cushing Syndrome)
- Current or past anti-psychotic drug use that would affect metabolism
- Non-diet treatment for hypertension or dyslipidemia
- Precocious puberty and/or receiving androgen and estrogen therapy
- Medication use known to affect body composition/weight
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- Dana-Farber Cancer Institutecollaborator
Study Sites (1)
Britni Ryan Belcher, PhD, MPH
Los Angeles, California, 90032, United States
Related Publications (3)
Belcher BR, Berrigan D, Papachristopoulou A, Brady SM, Bernstein SB, Brychta RJ, Hattenbach JD, Tigner IL Jr, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Children's Sedentary Behaviors With Activity on Metabolic Function: A Randomized Trial. J Clin Endocrinol Metab. 2015 Oct;100(10):3735-43. doi: 10.1210/jc.2015-2803. Epub 2015 Aug 27.
PMID: 26312582BACKGROUNDBroadney MM, Belcher BR, Berrigan DA, Brychta RJ, Tigner IL Jr, Shareef F, Papachristopoulou A, Hattenbach JD, Davis EK, Brady SM, Bernstein SB, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of Interrupting Sedentary Behavior With Short Bouts of Moderate Physical Activity on Glucose Tolerance in Children With Overweight and Obesity: A Randomized Crossover Trial. Diabetes Care. 2018 Oct;41(10):2220-2228. doi: 10.2337/dc18-0774. Epub 2018 Aug 6.
PMID: 30082324BACKGROUNDBelcher BR, McAlister KL, Zink J, Chapman TM, Moore KN, Castillo S, Hewus M, Kaslander JN, Dieli-Conwright CM, Huh J, Page KA. Design of a randomized controlled trial to test the efficacy of interrupting sitting on type 2 diabetes risk factors in children with overweight/obesity: The sedentary behavior study 3 protocol. Contemp Clin Trials. 2025 May;152:107862. doi: 10.1016/j.cct.2025.107862. Epub 2025 Feb 21.
PMID: 39987963DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
May 20, 2020
First Posted
July 14, 2020
Study Start
March 1, 2022
Primary Completion (Estimated)
July 31, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
June 5, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share